Quality Systems – Page 38

Artwork change error during scale-up – regulatory risk analysis and mitigation

Analysis and Mitigation of Artwork Change Errors During Scale-Up in Pharmaceutical Operations In the pharmaceutical manufacturing industry, the transition from small-scale production to full-scale operations is a critical period where…

AE reporting non-compliance during signal review – how to strengthen benefit–risk documentation

Addressing AE Reporting Non-Compliance During Signal Review for Enhanced Benefit-Risk Documentation Adverse Event (AE) reporting non-compliance during signal review represents a critical concern for pharmaceutical organizations facing regulatory scrutiny. The…

Material specification drift during market launch – how to prevent recall triggers

Understanding the Challenges of Material Specification Drift During Market Launch and Prevention Strategies In the fast-paced world of pharmaceutical production, material specification drift during market launch raises significant concerns that…

Periodic report inconsistencies during post-marketing surveillance – inspection questioning scenarios

Addressing Anomalies in Periodic Reports During Post-Marketing Surveillance Periodic report inconsistencies during post-marketing surveillance can pose significant challenges for pharmaceutical companies. These discrepancies, if left unaddressed, may not only lead…

Material specification drift during development – inspection evidence expectations

Understanding Material Specification Drift During Development: Evidence Expectations for Inspections Material specification drift during development can significantly impact the quality and consistency of pharmaceutical products. This phenomenon may lead to…

Periodic report inconsistencies during audit response – regulatory enforcement risk and mitigation

Addressing Inconsistencies in Periodic Reports During Audit Responses In the pharmaceutical industry, maintaining consistent and accurate periodic reports is crucial, especially during regulatory audits that are inherent to compliance with…

Material specification drift during scale-up – inspection evidence expectations

Understanding and Investigating Material Specification Drift During Scale-Up Material specification drift during scale-up can create significant challenges within pharmaceutical manufacturing, impacting product quality and regulatory compliance. As organizations strive for…

Tag: Quality Systems

Artwork change error during scale-up – regulatory risk analysis and mitigation

AE reporting non-compliance during signal review – how to strengthen benefit–risk documentation

Material specification drift during market launch – how to prevent recall triggers

Periodic report inconsistencies during post-marketing surveillance – inspection questioning scenarios

Material specification drift during development – inspection evidence expectations

Periodic report inconsistencies during audit response – regulatory enforcement risk and mitigation

Material specification drift during scale-up – inspection evidence expectations

Case processing backlog during benefit–risk assessment – how to strengthen benefit–risk documentation

Stability impact underestimated during scale-up – CAPA and control strategy

Risk management plan gaps during inspection – regulatory enforcement risk and mitigation

Container closure integrity risk during supplier change – regulatory risk analysis and mitigation

Packaging compatibility risk during supplier change – documentation gaps regulators question